CDSCO approves AstraZeneca’s anti-liver cancer drug combination, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Durvalumab alone. The trial showed a positive and significant benefit for OS for the combination of Tremelimumab & Durvalumab vs Sorafenib., The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Durvalumab alone. The trial showed a positive and significant benefit for OS for the combination of Tremelimumab & Durvalumab vs Sorafenib., , Read More